Categories Health Care, IPO

IPO news: Here are a few points to note as Amylyx Pharmaceuticals goes public this week

The company will offer 8.8 million shares at a price range of $18 to $20

There are quite a few pharmaceutical companies lined up to make their market debut this week. Among these is Amylyx Pharmaceuticals which is slated to go public this Friday. Here are a few points to note about this new IPO candidate:

IPO details

Amylyx Pharmaceuticals Inc. is scheduled to go public on Friday, January 7. The company will begin trading on NASDAQ under the ticker symbol AMLX. It will offer 8.8 million shares at a price range of $18 to $20. The IPO will be managed by a group of underwriters led by Goldman Sachs.

Company intro

According to its regulatory filings, Amylyx Pharmaceuticals is focused on developing therapies that change the treatment paradigm for amyotrophic lateral sclerosis (ALS) and a broad range of neurodegenerative diseases by keeping neurons alive. Most cells in the body tend to die regularly and be replaced as part of healthy function but mature neurons are normally resistant to cell death and generally cannot regenerate.

The company’s product candidate, AMX0035, is a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate (PB), and TURSO, also known as tauroursodeoxycholic acid, or TUDCA. Through the resolution of the unfolded protein response (UPR) and by inhibiting translocation of the Bcl-2 Associated X-protein (Bax) to the outer mitochondrial membrane, Amylyx has shown in multiple models that AMX0035 can keep neurons alive under a variety of different conditions and stresses.  

Amylyx submitted a New Drug Submission (NDS) in Canada in the second quarter of 2021 for AMX0035 for the treatment of ALS, which was accepted for review in the third quarter of 2021. It also submitted a New Drug Application (NDA) to the US FDA in the fourth quarter of 2021, which was accepted for priority review in the same quarter. The company intends to submit a Marketing Authorization Application (MAA) in Europe early in the first quarter of 2022. Amylyx is pursuing ALS as its first indication as it is a disease of rapid and profound neurodegeneration.

Financials

For the nine months ended September 30, 2021, Amylyx reported grant revenue of $285,000. Net loss amounted to $59.5 million compared to $33.6 million in the same period a year ago. Pro forma net loss per share amounted to $1.30. Total operating expenses were $54.6 million compared to $30.4 million in the year-ago quarter.

Market opportunity

Neurodegeneration is one of the most significant unmet medical needs today. The development of therapies that preserve neuron health has been challenging, mainly due to a rudimentary understanding of the underlying biology as well as results seen in preclinical studies not translating to clinical trials. The currently approved therapies generally modify only symptoms and have shown limited efficacy. There remains an urgent need for novel approaches to address most neurodegenerative diseases, especially severe conditions such as ALS.

Click here to read more IPO stories

Looking for more insights on the earnings results? Click here to access the full transcripts of the latest earnings conference calls!

Most Popular

HD Stock: What’s in store for Home Depot after record second quarter

Home improvement is one of the top activities that kept Americans busy during the pandemic, a trend that enabled The Home Depot, Inc. (NYSE: HD) to beat the crisis and

Target (TGT) stock drops after Q2 earnings miss estimates; revenue up 4%

Department store chain Target Corporation (NYSE: TGT) reported a sharp decline in adjusted earnings for the second quarter of 2022, despite an increase in net sales. The bottom line also fell

Amazon (AMZN) stock remains a good bet despite poor results. Here’s why

Amazon.com, Inc. (NASDAQ: AMZN) became an inspiration for other players in the eCommerce sector as the online retailer successfully channelized its resources to tap into the spike in demand for

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top